Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up.
Carroll
P
P
Department of Urology, University of California, San Francisco, Medical Center, San Francisco, California, USA.
Coley
C
C
McLeod
D
D
Schellhammer
P
P
Sweat
G
G
Wasson
J
J
Zietman
A
A
Thompson
I
I
D001842:Bone and Bones / Q000000981:diagnostic imaging; D017679:Cryotherapy; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008279:Magnetic Resonance Imaging; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009367:Neoplasm Staging / Q000379:methods*; D010388:Pelvis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000532:radiotherapy / Q000628:therapy; D011877:Radionuclide Imaging; D014057:Tomography, X-Ray Computed
D017430:Prostate-Specific Antigen